As confirmed by Western blot testing , there were 16 HSV-2 seroconversions among women assigned to tenofovir gel as compared with 36 among those assigned to the placebo gel ( incidence rate ratio , 0.45 ; 95 % CI , 0.23 to 0.82 ; P = 0.005 ) .